Company profile
Vaccinex, Inc.
OTC: VCNX · Healthcare · Biotechnology
#917 of 1,418 Healthcare companies by revenue50th-percentile growth
EA Score
——FH —DQ 35GM —SS 40
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, revenue growth (YoY) · ↓ return on assets, Altman-Z
Methodology →Revenue TTM
$601.0k
Rev growth YoY (TTM)
+226.6%
Net income (FY)
-$18.6M
Employees
25
as of 2026-08-24
Market cap
$2.9M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$601.0k$601.0k2024
Net income-$18.6M-$18.6M2024
Operating income-$18.7M-$18.7M2024
Total assets$2.6M$2.6M2024
Liabilities$5.1M$5.1M2024
Equity-$2.5M-$2.5M2024
Revenue trend
FY2018 – FY2024 · USD
FY18
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2023
By product
Exclusive Product License100%
By geography
Not disclosed.
The read
What is Vaccinex, Inc.’s revenue?
Vaccinex, Inc. booked $601.0k in FY2024 revenue, growing 5.4% year over year — about the middle of the pack among Healthcare companies we track, at a -3100.5% net margin.
Peers · Healthcare
Co-Diagnostics, Inc.33DNovelStem International Corp.37DTheralink Technologies, Inc.——CBD of Denver, Inc.35DCardiff Oncology, Inc.53DPMGC Holdings Inc.29DNeighbors
Monroe →Key facts
CEOMaurice Zauderer
SectorHealthcare
IndustryBiotechnology
HeadquartersRochester, NY
ExchangeOTC: VCNX
Employees25
IPO date2018-08-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.